WEBINAR 3
Q&A

We would like to thank those of you who joined and submitted questions along the way for Emerald Health Pharmaceuticals' third webinar in the ***Developing Medicines Based on Cannabinoid Science*** series.

Below you will find answers to the questions asked of the company as part of our webinar on May 28th, 2020. Please note that this document may contain some forward-looking statements, therefore we ask that you read the disclosure included at the end of this document. In case you missed the webinar, you can find it here.

If you have any questions, please feel free to reach out to our dedicated investor relations team at any time via email at invest@emeraldpharma.life or by phone 1.888.468.3471.

Thank you for your ongoing support of Emerald Health Pharmaceuticals.

Best Regards,
The Emerald Health Pharmaceuticals Team

Technology

Q: Do your molecules have to be administered exclusively to treat a condition or can they be blended into a "cocktail" to treat?

A: Since the FDA in the US and the appropriate regulatory agencies in other countries approve a drug such as ours based on clinical trials, the exact dosage and form of administration used in the clinical trials are specified for the indication approved. Any other dosage or form of administration, or combination with other therapies, must be tested in additional clinical studies.

Q: Of the 21 pending patents, how many do you expect to be fully granted?

A: There are numerous factors that go into the granting of a patent. Therefore, there is always a chance a patent may not be granted. To date, we have filed 38 patents, of which 17 US and international patents have already been granted. This shows thart we have experience in applying for patents to minimize potential challenges or delays.

Q: **Can cannabinoid anti-inflammatory effects improve chronic asthma?**

A: Cannabinoids have been shown anecdotally and in some studies with CBD to improve asthma and other inflammatory conditions. Here is a link to one such study: https://pubmed.ncbi.nlm.nih.gov/30481497/

Financing

Q: **Where do we go to invest? How do I contact you to invest in the company?**

A: Thank you for your interest and support! We are not currently offering sales of our common stock under our Regulation A+ offering, but we could decide to again in the future. Please sign up here and we will be sure to contact you if an additional offering becomes available.

Q: **How much are you raising this round, and how much has been committed?**

A: As we disclosed in our Annual Report on Form 1-K, as of April 15, 2020, we have raised $20.6M, and since that date, we have raised additional funds. The total amount raised through the closing of our most recent offering on June 6, 2020 will be announced in the next several weeks.

Q: **What valuation level is the offering at?**

A: The most recent financing was done at a valuation of approximately $90M under our Regulation A+offering, with each share priced at $6 per share. We arrived at the price of this offering by evaluating comparable companies developing products in similar disease areas and based on the completion and success of our Phase 1 clinical study.

Q: **Being a current stockholder, can I purchase more stock after the June 6th closing?**

A: Thank you for being a shareholder. Unfortunately, we cannot accept any investments after the June 6th deadline. We are considering opening up another offering in the second half of this year. Please sign up here and we will be sure to contact you if an additional offering becomes available.

Clinical Trials

Q. **How can we become part of a clinical study? Is there a way that I could get my sister or brother to sign up for the tests?**

A: At this time, we are only accepting patients for our EHP-101 systemic sclerosis study (we plan to start initiating a study in MS later this year). We have received

approval to begin the systemic sclerosis study and expect to start enrolling patients within the coming weeks - pending any delays due to COVID-19 - so we are on track. Please note that our first research centers for this Phase 2 clinical trial of EHP-101 for the treatment of systemic sclerosis will be located in the U.S., Australia, and New Zealand. A full list of study locations and contact information can be found at clinicaltrials.gov, identifier: NCT04166552.

You can find the eligibility criteria for the study on the clinicaltrials.gov website by clicking here, however you will need to speak directly with your doctor to determine eligibility. Additionally, you or your doctor may contact the study research staff using the contacts provided on the clinicaltrials.gov website to learn more information. The study identifier on clinicaltrials.gov is NCT04166552.

Q: Where is the US location going to be for the Phase II human study?

A: The systemic sclerosis Phase II study will be conducted in approximately 20 centers in the US. A full list of study locations and contact information will be posted at clinicaltrials.gov, identifier: NCT04166552.

General

Q: Can you identify the scientific journals with EHP data?

A: Our work in cannabinoid science has been well-received by the scientific community and published by independent, credible scientific journals. You can find the full list of journals on our website here.

Q: Please explain the difference between Emerald Health Pharmaceutical and Emerald Bioscience. Is there redundancy/overlap?

A: No, there is no overlap. Emerald Bioscience (EMBI), and Emerald Health Pharmaceuticals (EHP) operate as separate entities. EMBI is a public company, while EHP is a private company.

The basis of the technologies between EHP and EMBI is also different. EHP uses synthetic CBD and CBG to create new derivative molecules, which have been modified to target and modulate the activity of key biologic receptors and physiologic pathways throughout the body, both within the endocannabinoid system and outside the endocannabinoid system, which have been shown to affect many diseases with unmet medical needs, specifically devastating neurodegenerative, inflammatory, autoimmune and fibrotic diseases. EMBI, on the other hand, uses a prodrug of THC and an analog of CBD for the treatment of localized ocular diseases, such as glaucoma and infectious diseases, such as MRSA.

Q: **Is Emerald Health Pharmaceuticals looking for clinical research support staff to manage sites, CROs, budgets and timelines?**

A: At this time, we are not hiring any additional personnel. We have the right staff in place to continue to efficiently and effectively advance our clinical trials and meet our goals and objectives. If new job openings come up, they will be posted on our website at www.emeraldpharma.life.

Q: **Will you be posting the webinar's slide deck on the website for investors?**

A: The webinar, which will include the slides, can be found on our website in our Newsroom. The slides are also part of EHP's corporate deck, which you can view by clicking here.

Forward Looking Statements

To the extent the above statements are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the private securities litigation reform act of 1995, that reflect management's current beliefs and expectations. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "hope," "hypothesis," "intend," "may," "plan," "potential," "predict," "project," "should," "strategy," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.